BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Down 46.6% in May

BioLineRx Ltd. (NASDAQ:BLRXGet Free Report) was the target of a significant drop in short interest in May. As of May 15th, there was short interest totalling 219,100 shares, a drop of 46.6% from the April 30th total of 410,600 shares. Based on an average trading volume of 410,600 shares, the days-to-cover ratio is presently 0.5 days.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on BLRX shares. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of BioLineRx in a research report on Wednesday. StockNews.com upgraded BioLineRx to a “sell” rating in a research report on Tuesday, April 23rd.

Check Out Our Latest Stock Report on BioLineRx

BioLineRx Stock Up 5.7 %

BioLineRx stock traded up $0.04 during trading on Thursday, reaching $0.73. 192,655 shares of the company were exchanged, compared to its average volume of 383,064. BioLineRx has a 52-week low of $0.55 and a 52-week high of $2.53. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.47 and a current ratio of 1.53. The stock’s 50 day simple moving average is $0.75 and its two-hundred day simple moving average is $1.17.

BioLineRx (NASDAQ:BLRXGet Free Report) last posted its earnings results on Tuesday, May 28th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.28. The business had revenue of $6.86 million during the quarter, compared to analysts’ expectations of $0.34 million. During the same quarter in the prior year, the firm earned ($0.15) EPS. As a group, research analysts anticipate that BioLineRx will post -1.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. B. Riley Wealth Advisors Inc. grew its stake in BioLineRx by 88.5% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 10,000 shares in the last quarter. NorthRock Partners LLC acquired a new position in BioLineRx during the 4th quarter worth $27,000. Allen Mooney & Barnes Investment Advisors LLC acquired a new position in BioLineRx during the 3rd quarter worth $46,000. Rathbones Group PLC acquired a new position in shares of BioLineRx during the 3rd quarter worth about $72,000. Finally, Values First Advisors Inc. acquired a new position in shares of BioLineRx during the 3rd quarter worth about $88,000. 1.56% of the stock is owned by institutional investors and hedge funds.

BioLineRx Company Profile

(Get Free Report)

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

Featured Stories

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.